Delayed-Type Hypersensitivity Testing for Medical Devices: ISO 10993-10 Sensitization Evaluation

Delayed-type hypersensitivity (DTH) testing is a critical biocompatibility study required to evaluate whether medical devices can induce Type IV allergic skin reactions in patients. Conducted in accordance with ISO 10993-10 and related national standards, this evaluation is mandatory for regulatory submissions worldwide, covering devices that contact skin, mucous membranes, or internal tissues. This article provides a comprehensive overview of delayed-type hypersensitivity testing for medical devices, including applicable sample types, test methods such as the Guinea Pig Maximization Test and Buehler assay, and practical guidance for biological safety evaluation.

Technical Overview

Delayed-type hypersensitivity (DTH), also known as Type IV hypersensitivity or allergic contact sensitization, is a cell-mediated immune response driven by T lymphocytes rather than antibodies. Unlike immediate hypersensitivity reactions, DTH symptoms typically appear 24 to 72 hours after re-exposure to a sensitizing substance, manifesting as erythema, edema, and induration at the contact site.

For medical devices, the primary concern is that leachable chemical substances—including residual monomers, plasticizers, accelerators, sterilant residues, metal ions, and degradation products—may penetrate the skin or mucosa and trigger sensitization in patients following single or repeated exposure. DTH testing is therefore a core component of the biological evaluation program described in ISO 10993-1, with specific test procedures defined in ISO 10993-10 (Tests for skin sensitization) and sample preparation requirements defined in ISO 10993-12.

Key elements of the evaluation framework include:

• ISO 10993-10: Biological evaluation of medical devices — Part 10: Tests for skin sensitization
• ISO 10993-12: Biological evaluation of medical devices — Part 12: Sample preparation and reference materials
• ISO 10993-1: Framework for risk management and endpoint selection in biological safety evaluation
• GB/T 16886.10: The Chinese national standard series harmonized with ISO 10993-10
• OECD Test Guidelines 406, 429, and 442 series: Reference methods for sensitization hazard identification

Regulatory authorities worldwide, including the US FDA, European notified bodies operating under the EU MDR, and China NMPA, require sensitization data for most device categories involving patient contact. Testing is generally performed by accredited third-party laboratories or in-house facilities operating under GLP-compliant quality systems.

Testing Samples

Surface-Contacting Devices

Devices with prolonged or repeated contact with intact skin constitute a major category for DTH evaluation. Typical examples include adhesive bandages, wound dressings, surgical tapes, electrode gels and pads, compression garments, examination and surgical gloves, face masks, and immobilization devices. Because these products apply materials directly onto compromised or intact skin for extended durations, the sensitization risk from adhesives, residual chemicals, and elastomer additives must be characterized.

External Communication Devices

Devices that interface with the circulatory system or mucosal tissues require sensitization assessment due to higher exposure risk. Representative samples include intravenous catheters, infusion sets, extension tubing, blood oxygenators, hemodialyzers, endoscopes and their sheaths, urinary catheters, tracheal tubes, and contraceptive devices. Leachables entering the bloodstream or contacting mucosa systemically can induce T-cell-mediated responses even at low concentrations.

Implantable Devices

Long-term implants present cumulative exposure scenarios that demand rigorous sensitization testing. Samples in this category include orthopedic implants and fixation hardware, dental materials and implants, cardiovascular stents and grafts, breast implants, intraocular lenses, absorbable sutures, scaffolds, and drug-device combination products. Metal ions such as nickel, cobalt, and chromium released from metallic implants are well-documented causes of delayed hypersensitivity.

Raw Materials and Components

Individual polymers, elastomers, ceramics, metals, coatings, curing agents, adhesive layers, packaging materials that contact the product, and process chemicals may be submitted as standalone samples. Early-stage material screening through DTH testing supports material selection and supplier qualification during product development, reducing late-stage regulatory risk.

Testing Items

The core objective of the delayed-type hypersensitivity test is to determine whether a device or its extracts possess skin sensitization potential following repeated exposure. The standard testing scope includes:

• Sensitization potential of polar extracts (typically 0.9% sodium chloride injection or physiological saline)
• Sensitization potential of non-polar extracts (typically sesame seed oil or other vegetable oil complying with pharmacopoeial specifications)
• Additional extraction media where justified, such as ethanol/water mixtures or culture media for specific material chemistries
• Skin reaction grading for erythema and edema at challenge sites according to standardized scales
• Comparison of response incidence and severity between test and control groups
• Statistical and biological evaluation to classify the material as a sensitizer or non-sensitizer

Where soluble metals or specific extractables are anticipated, acidified saline or other tailored media may be justified with documented scientific rationale, consistent with ISO 10993-12 and regulatory expectations.

Testing Methods

Sample Preparation and Extraction

Test articles are extracted under conditions intended to exaggerate clinical exposure while avoiding material degradation. Standard extraction conditions include 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, selected according to the temperature tolerance of the material and the device's clinical use conditions. Extraction ratios follow the surface-area or mass-based tables in ISO 10993-12, ensuring standardized dose delivery. Both polar and non-polar extracts are prepared and tested in parallel whenever the material composition supports extraction in both media.

Guinea Pig Maximization Test (GPMT)

The Guinea Pig Maximization Test, based on the Magnusson-Kligman method, is the most widely accepted in vivo procedure for medical device sensitization and is the preferred method in ISO 10993-10. The assay uses Freund's Complete Adjuvant combined with intradermal injection to maximize immune stimulation. The procedure involves:

• Intradermal induction on day 0, using test extract, adjuvant, and extract-adjuvant emulsion at clipped sites
• Topical induction approximately one week later, following pretreatment with sodium lauryl sulfate to enhance penetration
• A rest period of approximately two weeks allowing immune memory development
• Topical challenge with the test extract on a naive flank site
• Grading of challenge sites at 24, 48, and optionally 72 hours after patch removal using the Magnusson-Kligman scale from 0 (no visible change) to 3 (intense erythema and swelling)

A typical design employs ten animals in the test group and five in the control group, with expanded group sizes where weak responses are anticipated. A positive response in a sufficient number of test animals, absent in controls, identifies the sample as a sensitizer.

Buehler Closed Patch Test

The Buehler test applies samples epicutaneously under occlusive patches without adjuvant, simulating a realistic skin exposure route. Induction consists of three weekly 6-hour occlusive exposures, followed by a two-week rest period and a challenge patch on a previously unexposed site. Reaction sites are graded at 24 and 48 hours after patch removal. ISO 10993-10 considers the Buehler method particularly suitable for devices intended for intact skin contact and for materials where adjuvant-enhanced exposure is not clinically justified.

Murine Local Lymph Node Assay (LLNA)

The LLNA offers a reduced-animal alternative based on the measurement of lymphocyte proliferation in the draining auricular lymph nodes following topical application of the test substance. Proliferation is quantified either by radiolabeled thymidine incorporation or by ATP measurement using bioluminescence, with a stimulation index of 3 or greater indicating sensitization potential. While established for chemicals under OECD Test Guideline 429 and 442 protocols, the applicability of the LLNA to device extracts must be justified, as aqueous extracts may exhibit limited solubility in the vehicle systems used. The method delivers faster turnaround and fewer animals when scientifically appropriate.

Result Interpretation

Laboratories classify outcomes by integrating the incidence and magnitude of responses in test versus control animals, with grading performed blind to treatment where feasible. A grade 1 response in a single test animal may warrant re-challenge or study repetition to confirm the finding. Final conclusions are documented in a biological evaluation report aligned with the overall risk management file for the device.

Applications

Delayed-type hypersensitivity test reports serve multiple regulatory and quality purposes throughout the medical device lifecycle:

• Regulatory submissions to authorities such as US FDA premarket notifications and approvals, CE marking technical documentation under the EU Medical Device Regulation, China NMPA registration dossiers, and submissions to other national agencies
• Biological safety evaluation files demonstrating conformity with the ISO 10993-1 risk management framework
• Verification following material changes, supplier changes, formulation adjustments, or modifications to sterilization and processing methods
• Material screening during research and development to eliminate sensitizing candidates before clinical exposure
• Support for toxicological risk assessments based on extractables and leachables data generated under ISO 10993-18 chemical characterization
• Compliance demonstration for products distributed across multiple jurisdictions with differing standard adoption timelines

Because sensitization is a mandatory endpoint for the vast majority of body-contacting devices, a compliant DTH study is foundational to market access in nearly all major regulatory regions.

FAQ

What is the difference between sensitization and irritation testing?

Irritation evaluates a localized, non-immune inflammatory reaction from a single exposure, whereas sensitization evaluates an immune-mediated response that develops only after repeated exposure and requires an induction period. Sensitization reactions are typically delayed, appearing 24 to 72 hours after challenge, and are governed by T-cell memory mechanisms. The two endpoints are assessed under separate parts of the ISO 10993 series, with sensitization addressed in ISO 10993-10.

How should a manufacturer choose between GPMT, Buehler, and LLNA methods?

The GPMT is the most sensitive in vivo method and is generally expected for devices with prolonged mucosal, breached surface, or internal contact. The Buehler test suits devices contacting intact skin under realistic occlusive exposure. The LLNA provides a faster, animal-reducing alternative when extract chemistry permits valid topical administration. Method selection should be documented with scientific justification and confirmed against the expectations of the target regulatory market.

What is the typical study duration?

A GPMT or Buehler study generally requires six to eight weeks from animal receipt through final grading, in addition to the extraction period and report preparation time. An LLNA study can be completed in a shorter timeframe, often within two to three weeks including acclimatization. Sponsors should also account for scheduling and animal availability when planning regulatory timelines.

Why are both polar and non-polar extracts tested?

Device leachables span a broad range of chemical polarities. Saline extracts capture water-soluble substances such as salts, acids, and polar residuals, while vegetable oil extracts capture lipophilic substances such as plasticizers, oligomers, and process additives. Testing both media ensures comprehensive coverage of potentially sensitizing extractables, as required by ISO 10993-12.

Can sensitization testing be waived?

Waiver is possible in limited circumstances where existing data on identical materials, documented chemical characterization, and toxicological risk assessment demonstrate an adequate margin of safety, or where the device has no patient contact. Such justification must be documented by a qualified toxicologist within the biological evaluation report and accepted by the relevant regulatory authority, consistent with ISO 10993-1 and ISO 10993-2 ethical review principles.

What follow-up actions are required if a sample produces a positive result?

A positive sensitization finding requires risk mitigation before market authorization. Typical actions include reformulating the material, changing suppliers or processing parameters, adding purification or post-curing steps, reducing extractables through improved cleaning, or conducting chemical characterization to identify the causative agent. Retesting of the modified device is then performed to confirm that sensitization potential has been eliminated or reduced to an acceptable level.